Jacobs Levy Equity Management Inc. Invests $1.61 Million in Opko Health Inc. (NASDAQ:OPK)
Jacobs Levy Equity Management Inc. acquired a new position in shares of Opko Health Inc. (NASDAQ:OPK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,095,334 shares of the biotechnology company’s stock, valued at approximately $1,610,000.
Several other hedge funds have also bought and sold shares of OPK. Charles Schwab Investment Management Inc. raised its position in shares of Opko Health by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,462,420 shares of the biotechnology company’s stock worth $3,620,000 after buying an additional 25,271 shares during the period. American International Group Inc. raised its position in shares of Opko Health by 7.2% in the 4th quarter. American International Group Inc. now owns 241,456 shares of the biotechnology company’s stock worth $355,000 after buying an additional 16,259 shares during the period. Millennium Management LLC raised its position in Opko Health by 4,068.8% in the third quarter. Millennium Management LLC now owns 455,318 shares of the biotechnology company’s stock valued at $951,000 after purchasing an additional 444,396 shares during the period. California Public Employees Retirement System raised its position in Opko Health by 35.8% in the third quarter. California Public Employees Retirement System now owns 681,627 shares of the biotechnology company’s stock valued at $1,425,000 after purchasing an additional 179,782 shares during the period. Finally, Alpine Global Management LLC purchased a new position in Opko Health in the fourth quarter valued at about $61,000. Institutional investors and hedge funds own 26.28% of the company’s stock.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 22,262 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were acquired at an average cost of $1.56 per share, with a total value of $34,728.72. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $4,787,563.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders acquired 1,437,501 shares of company stock worth $2,169,859 over the last three months. 42.25% of the stock is currently owned by corporate insiders.
NASDAQ:OPK opened at $1.36 on Thursday. The business’s 50-day moving average is $1.64 and its two-hundred day moving average is $1.68. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.30 and a quick ratio of 1.09. Opko Health Inc. has a 12 month low of $1.33 and a 12 month high of $2.91. The firm has a market capitalization of $951.16 million, a PE ratio of -2.57 and a beta of 1.99.
Opko Health Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Further Reading: Monthly Dividend Stocks
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NASDAQ:OPK).
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.